Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.0)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 611–615

doi: 10.17219/acem/62430

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Formation of Blood Vessel After the Administration of the Plasmid Encoding Ang-1 Gene in Fischer Rats

Jan P. Skóra1,A,B,C,D,E,F, Tomasz Płonek2,B,C,D,E, Piotr Barć1,B,C,D, Dagmara Baczyńska3,4,B,C, Agata Radwańska4,B,C, Artur Pupka1,A,C, Krzysztof Korta1,B,D, Marek Ussowicz5,C,E, Łukasz Strożecki6,C, Diana Kupczyńska-Markiewicz1,A, Agnieszka Hałoń7,A,B,C,E,F

1 Department of Vascular, General and Transplantation Surgery, Wroclaw Medical University, Poland

2 Department of Cardiac Surgery, Wroclaw Medical University, Poland

3 Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Poland

4 Wrovasc – Integrated Cardiovascular Centre, Regional Specialist Hospital in Wrocław, Research and Development Centre, Poland

5 Department of Pediatric BMT, Oncology and Hematology, Wroclaw Medical University, Poland

6 Department of Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Poland

7 Department of Pathology, Wroclaw Medical University, Poland

Abstract

Background. Chronic limb ischemia is a serious clinical problem. Patients who do not qualify for standard treatment may benefit from novel gene therapies.
Objectives. This study evaluated angiogenesis following intramuscular injections of angiogenic plasmid Ang-1 in Fisher rats.
Material and Methods. Twenty rats had plasmids injected intramuscularly in their hind limbs. The study group consisted of 10 animals which received the Ang-1 plasmid, while the control group consisted of 10 rats that received an empty plasmid. All the animals were euthanized after 12 weeks and tissue samples from the hind limb thigh muscles and internal organs were harvested for histological and immunohistochemical examinations. To assess the angiogenesis the number of vessels in the hind limb muscles visualized by the SMA and FVIII markers was counted for each animal in five separate microscopic fields.
Results. There were no pathological lesions or any signs of neoplastic angiogenesis in any of the 20 rats. The number of vessels visualized by the FVIII marker in the study group was two times higher than in the control group (median: 12, range: 7–25 vs. median: 6, range: 2–15; p < 0.0001). The median estimated that the number of vessels visualized by the SMA marker is 63% higher in the study group compared to the control group (median: 6.5, range: 1–12 vs. median: 4, range: 0–10; p = 0.0008).
Conclusion. Intramuscular injections of Ang-1 plasmids induced angiogenesis in the rat hind limb muscles.

Key words

angiogenesis, lower limb ischemia, rats, proangiogenic factors

References (24)

  1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Group TIW, Bell K, Caporusso J, Durand-Zaleski I: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33, Suppl 1, S1–75.
  2. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the Ameri
  3. Iida O, Nakamura M, Yamauchi Y, Kawasaki D, Yokoi Y, Yokoi H, Soga Y, Zen K, Hirano K, Suematsu N: Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv 2013, 6, 68–76.
  4. Rowlands TE, Donnelly R: Medical therapy for intermittent claudication. Eur J Vasc Endovasc Surg 2007, 34, 314–321.
  5. Anghel A, Mut-Vitcu B, Savu L, Marian C, Seclaman E, Iman R, Neghina AM, Dragulescu SI: Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia. Genome Med 2007, 1, 47–55.
  6. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, Kojima H, Iwasaka T: Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 2002, 106, 2019–2025.
  7. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348, 370–374.
  8. Losordo DW, Dimmeler S: Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 2004, 109, 2487–2491.
  9. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M: Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002, 90, 966–973.
  10. Onimaru M, Yonemitsu Y, Tanii M, Nakagawa K, Masaki I, Okano S, Ishibashi H, Shirasuna K, Hasegawa M, Sueishi K: Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002, 91, 923–930.
  11. Chen F, Tan Z, Dong CY, Li X, Xie Y, Wu Y, Chen X, Guo S: Combination of VEGF(165)/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. Eur J Pharmacol 2007, 568, 222–230.
  12. Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, Stewart DJ: Angiogenic actions of angiopoietin1 require endothelium-derived nitric oxide. Am J Pathol 2003, 162, 1927–1936.
  13. Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, Yamaguchi T, Ogihara T, Morishita R: Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010, 17, 1152–1161.
  14. Zhu WH, MacIntyre A, Nicosia RF: Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am J Pathol 2002, 161, 823–830.
  15. Kobayashi K, Kondo T, Inoue N, Aoki M, Mizuno M, Komori K, Yoshida J, Murohara T: Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler Thromb Vasc Biol 2006, 26, 1465–1472.
  16. Shen F, Walker EJ, Jiang L, Degos V, Li J, Sun B, Heriyanto F, Young WL, Su H: Coexpression of angiopoietin1 with VEGF increases the structural integrity of the blood-brain barrier and reduces atrophy volume. J Cereb Blood Flow Metab 2011, 31, 2343–2351.
  17. Smith AH, Kuliszewski MA, Liao C, Rudenko D, Stewart DJ, Leong-Poi H: Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid. J Am Coll Cardiol 2012, 59, 1320–1328.
  18. Seo JH, Yu JH, Suh H, Kim MS, Cho SR: Fibroblast growth factor-2 induced by enriched environment enhances angiogenesis and motor function in chronic hypoxic-ischemic brain injury. PloS one 2013, 8, e74405.
  19. Yang ZJ, Ma DC, Wang W, Xu SL, Zhang YQ, Chen B, Zhou F, Zhu TB, Wang LS, Jia EZ: Neovascularization and cardiomyocytes regeneration in acute myocardial infarction after bone marrow stromal cell transplantation: Comparison of infarct-relative and noninfarct-relative arterial approaches in swine. Clin Chim Acta 2007, 381, 114–118.
  20. Dallabrida SM, Zurakowski D, Shih SC, Smith LE, Folkman J, Moulton KS, Rupnick MA: Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun 2003, 311, 563–571.
  21. Ho TK, Rajkumar V, Black CM, Abraham DJ, Baker DM: Increased angiogenic response but deficient arteriolization and abnormal microvessel ultrastructure in critical leg ischaemia. Br J Surg 2006, 93, 1368–1376.
  22. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1–8.
  23. Yamauchi A, Ito Y, Morikawa M, Kobune M, Huang J, Sasaki K, Takahashi K, Nakamura K, Dehari H, Niitsu Y: Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 2003, 5, 994–1004.
  24. Siddiqui AJ, Blomberg P, Wardell E, Hellgren I, Eskandarpour M, Islam KB, Sylven C: Combination of angiopoietin1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res Commun 2003, 310, 1002–1009.
© Wroclaw Medical University